Advertisement
JNJ vs MRK
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- JNJ offers diversified exposure across pharmaceuticals and MedTech, providing relative stability amid sector volatility.
- MRK demonstrates stronger year-to-date momentum driven by oncology leadership and pipeline advancements.
- Both companies report solid revenue growth in recent quarters, though MRK faces higher valuation multiples reflecting growth expectations.
- Sector sentiment remains constructive for healthcare, with positive clinical data supporting sentiment for both stocks in recent weeks.
- Relative performance shows MRK outperforming JNJ on a year-to-date basis, while JNJ exhibits lower volatility.
- Market positioning highlights trade-offs between JNJ’s breadth and MRK’s focused growth catalysts.
Introduction
Johnson & Johnson (JNJ) and Merck & Co. (MRK) represent two leading healthcare companies frequently compared by investors seeking exposure to pharmaceuticals and medical innovation. This analysis examines their recent stock behavior, business fundamentals, and relative positioning in the current market environment. Traders and long-term investors evaluating defensive growth opportunities or sector rotation strategies within healthcare may find this comparison relevant for assessing diversification, momentum, and risk profiles.
JNJ Overview and Recent Performance
Johnson & Johnson operates across pharmaceuticals and MedTech segments, with key products in oncology, immunology, and surgical devices. In recent weeks, the stock has traded near $265–$270 amid mixed session-to-session moves, reflecting broader healthcare sector dynamics. Positive clinical updates, including extended survival data for RYBREVANT in lung cancer and new CE marking for contact lenses, have supported sentiment. The company continues to advance its pipeline and execute on MedTech initiatives, contributing to steady operational performance amid a market environment favoring established healthcare names.
MRK Overview and Recent Performance
Merck & Co. focuses primarily on pharmaceuticals, with oncology as a core driver through KEYTRUDA and related assets. The stock has shown resilience in recent market activity, trading around $144–$150 following pipeline milestones and earnings updates. Recent developments include positive Phase 3 results in melanoma combinations and guidance adjustments reflecting acquisition impacts. These factors have contributed to sustained investor interest, positioning the company amid ongoing sector rotation toward growth-oriented biopharma plays.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section featuring select AI trading bots optimized for prevailing market conditions. The platform offers hundreds of AI trading bots that execute strategies across thousands of tickers, yet only those demonstrating superior adaptability, statistical robustness, and alignment with current trends earn placement in this highlighted area. Available bots span diverse styles, timeframes, performance metrics, and ticker sets, enabling users to evaluate options suited to varying risk tolerances and objectives. Review the Trending AI Robots page for detailed statistics and live performance data.
Head-to-Head Comparison
Johnson & Johnson maintains a broader business model spanning pharmaceuticals and MedTech, offering diversified revenue streams compared to Merck’s concentrated focus on innovative oncology therapies. Recent momentum favors MRK, which has delivered stronger year-to-date returns amid pipeline catalysts, while JNJ exhibits greater price stability. Risk factors include litigation exposure for JNJ and patent dynamics for MRK. Both maintain significant sector exposure within healthcare, though MRK carries higher valuation multiples reflective of growth expectations, presenting a trade-off between defensive breadth and targeted upside potential.
Tickeron AI Verdict
Based on observable factors such as trend consistency and relative positioning in recent market activity, Tickeron’s AI models currently assign a higher probabilistic preference to MRK due to its stronger momentum profile and pipeline-driven catalysts, while acknowledging JNJ’s stability advantages in a balanced assessment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and MRK is a Hold.
JNJ | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 12 Undervalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 32 | |
SMR RATING 1..100 | 37 | 79 | |
PRICE GROWTH RATING 1..100 | 42 | 39 | |
P/E GROWTH RATING 1..100 | 10 | 2 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (11) in the Pharmaceuticals Major industry is in the same range as JNJ (12). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as MRK (32). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
JNJ's SMR Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that JNJ’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as JNJ (42). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as JNJ (10). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | MRK | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 38% |
| Stochastic ODDS (%) | 2 days ago 46% | 1 day ago 67% |
| Momentum ODDS (%) | 2 days ago 45% | 1 day ago 54% |
| MACD ODDS (%) | 2 days ago 36% | 1 day ago 50% |
| TrendWeek ODDS (%) | 2 days ago 39% | 1 day ago 49% |
| TrendMonth ODDS (%) | 2 days ago 44% | 1 day ago 42% |
| Advances ODDS (%) | 4 days ago 47% | 10 days ago 58% |
| Declines ODDS (%) | 2 days ago 40% | 1 day ago 51% |
| BollingerBands ODDS (%) | 2 days ago 37% | N/A |
| Aroon ODDS (%) | 2 days ago 46% | 1 day ago 64% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green while MRK’s FA Score has 3 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 2 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).
- JNJ’s TA Score: 2 bullish, 6 bearish.
- MRK’s TA Score: 3 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -4.44% price change this week, while MRK (@Pharmaceuticals: Major) price change was -2.82% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.29%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was +9.05%.
Reported Earning Dates
JNJ is expected to report earnings on Oct 13, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.29% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.